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& dhfrXII) and chloramphenicol (catB3) and correlated to
their antimicrobial susceptibility phenotypes. A new combi-
nation of gene cassettes (dfrA15- aadA1) was found in one
of the strains studied. The complete sequences of these
gene cassettes have been submitted to the GenBank and
Accession Numbers have been assigned.
doi:10.1016/j.ijid.2008.05.1055
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Risk Factors for Nephrotoxicity associated with Con-
tinuous Vancomycin Infusion in Outpatient Parenteral
Antibiotic Therapy
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Background: Continuous vancomycin infusion is increas-
ingly used for outpatient management of infections, but the
relationship between vancomycin and nephrotoxicity is con-
troversial. We investigated the risk factors associated with
nephrotoxicity in this setting.
Methods: A retrospective cohort study of patients receiv-
ing continuous vancomycin infusion as Outpatient Parenteral
Antibiotic Therapy (OPAT) was performed. The likelihood
of developing nephrotoxicity (≥50% increase in serum
creatinine from baseline) was evaluated in relation to
demographic variables, underlying co-morbidities, infec-
tious disease diagnoses, concomitant drug exposures and
vancomycin concentration. Logistic regression was used to
determine the association of various variables. Classiﬁcation
and regression tree analysis was used to determine the most
signiﬁcant breakpoint for continuous variables.
Results: We examined 102 adult patients between Jan-
uary 2004 and June 2007. The mean± SD age, baseline
serum creatinine and steady state vancomycin concen-
tration were 48.2± 17.6 years, 78.0± 32.5mol/L and
15.5± 10.8mg/L, respectively. The majority of the patients
(66.7%) were treated for bone and joint infection.
The cumulative incidence of nephrotoxicity was 15.7%.
Nephrotoxicity was found to be associated with hyper-
tension [odds ratio (OR) 5.302 (95% conﬁdence interval
{CI}1.159—24.246), p = 0.031], exposure to aminoglycosides
[OR 6.594 (95% CI 1.026—42.385), p = 0.047], loop diuret-
ics [OR 8.123 (95% CI 1.449—45.528), p = 0.017], and steady
state vancomycin concentration≥ 28mg/L [OR 21.236 (95%
CI 2.687—167.857), p = 0.004].
Conclusion: We have identiﬁed independent risk factors
for nephrotoxicity in patients receiving continuous infusion
vancomycin in OPAT. A serum steady state vancomycin con-
centration≥ 28mg/L markedly increases this risk.
doi:10.1016/j.ijid.2008.05.1056
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Comparative Study of Piperacillin/Tazobactam and
Cefepime in Cancer Patients with Febrile Neutropenia
Y.M. Wi ∗, D.R. Chung, J.H. Song, K.R. Peck
Samsung Medical Center, Seoul, Republic of Korea
Background: To compare the efﬁcacy and safety of
piperacillin/tazobactam with cefepime as an empiri-
cal monotherapy for adult cancer patients with febrile
neutropenia. Method: A prospective, randomized, open-
labelled, comparative trial was performed. If clinically
preferable, the test article may be changed to oral
ciproﬂoxacin at 72 hours. Clinical and microbiological
responses were determined at 72 hours and at the end of
therapy.
Results: A total of 89 cases were enrolled. 48 patients
received piperacillin/tazobactam (PT group) and 41 patients
received cefepime (CA group). Demographic and clinical
characteristics were similar in two groups (p > 0.05). Clin-
ical success rate at 72 hours in PT group (91.7%) was similar
to that in CA group (85.4%) (p = 0.31). At the end of therapy,
clinical success rate in PT group (91.7%) was also similar to
that in CA group (100%) (p = 0.15). Adverse events including
liver dysfunction (21.3%) and renal dysfunction (2.2%) were
similar in two groups (p = 0.87).
Conclusion: piperacillin/tazobactammonotherapy was as
effective and safe as the cefepime as an empirical treatment
for cancer patients with febrile neutropenia.
doi:10.1016/j.ijid.2008.05.1057
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Cationic antimicrobial peptides (AMPs) are important
mediators in the primary host defense system against
pathogenic microorganisms and are widely distributed
in nature. The occurrence and characterization of low-
molecular-mass AMPs from a wide variety of organisms have
been accumulating at a rapid rate because of their biochem-
ical diversity and broad speciﬁcity against bacteria or fungi
and even some being anti-viral or possessing wound-healing
effects. This has biopharmaceutical applications especially
in view of the increased bacterial resistance to antibiotics in
the clinical setting over the past decade. There is a growing
need to discover and introduce new drugs, and AMPs provide
new promising candidates as new antibiotics. The objective
of this study has been to isolate novel peptides from native
microbial and plant sources including fermented extracts.
The antimicrobial properties of these extracts were ini-
tially tested using Escherichia coli, Staphylococcus aureus
and Bacillus subtilis. This paper shows the initial results of
the inhibition obtained on these microorganisms using plant
and fermented extracts. The extracts were fractionated
using cation exchange chromatography and antimicrobial
tests were conducted with the fractions obtained. High pres-
sure liquid chromatography was attempted with one of the
extracts and some preliminary results were also obtained.
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Further studies that are in progress are also brieﬂy outlined
to indicate the potential of developing these compounds into
biopharmaceuticals.
doi:10.1016/j.ijid.2008.05.1058
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Objective: The aim of this study was to determine ability
of Iranian microbiology laboratories for identiﬁcation and
susceptibility testing of two unknown microorganisms.
Methods: In Feb 2007 21th run of proﬁciency test-
ing of Iranian microbiology laboratories carried out by
Iranian health reference laboratories. In this survey two
unknown microorganisms including Salmonella Paratyphi
B and Staphylococcus aureus were submitted to 1305
microbiology laboratories. We asked all laboratories to
identify each microorganism and performance of suscepti-
bility testing just for S. paratyphi B against tetracycline,
nalidixic acid, ciproﬂoxacin, ampicillin and trimethoprim-
sulfamethoxazole. Scoring of results performed according to
WHO criteria. The maximum score of point for identiﬁcation
of each bacterium was 3 score and 5 score for suscepti-
bility testing (each antibiotic one score). The results were
analyzed by SPSS.
Results: Of 1305 laboratories only 1122 (.86%) laborato-
ries participated in our survey and 183 (14%) laboratories
did not participated in this study. Of 1122 laboratories,
523 (46.6%) laboratories identiﬁed S. paratyphi B cor-
rectly and obtained maximum 3 score of points and 488
(43.5%) laboratories partially identiﬁed this microorgan-
ism (1—2.5 score) and 111 (9.9%) laboratories misidentiﬁed
this microorganism. The mean score was 2.6. The results
of susceptibility testing of S. paratyphi B were relatively
satisﬁed for nalidixic acid, ciproﬂoxacin and trimethoprim-
sulfamethoxazole. However the results of susceptibility
testing for tetracycline and ampicillin were unsatisﬁed and
only the results of 578 (52.5%) of 1122 were correct for tetra-
cycline and 558 (49.7%) of laboratories reported correct
answer for ampicillin. The mean of score for susceptibility
testing was 3.88. Regarding to identiﬁcation Staphyloco-
cus aureus of 1122 laboratories 767 (68.4%) identiﬁed this
organism correctly and obtained maximum three score,
211 (18.8%) laboratories reported partially correct answer
(1—2.5 score) and 114 (12.8%) laboratories could not iden-
tiﬁed S.aureus. in total mean score for identiﬁcation of this
microorganism was 2.3.
Conclusions: This study revealed that the majority of
microbiology laboratories were able for identiﬁcation of S.
parathyphi B and S. aureus. Nearly 50% of laboratories pro-
duced incorrect susceptibility testing answer according to S.
paratyphi B for tetracycline and ampicillin.
doi:10.1016/j.ijid.2008.05.1059
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Multicenter Evaluation of Tigecycline Activity in India:
Report from the SENTRY Antimicrobial Surveillance Pro-
gram (2006)
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Background: Tigecycline, the initial representative of
the glycylcyclines, presents a therapy option for emerging
multidrug-resistant (MDR) pathogens. India, a nation rarely
monitored in global surveillance programs, appears in need
of agents active against MDR isolates of Enterobacteriaceae
(ESBLs), Acinetobacters (carbapenem-resistant) and Gram-
positive cocci (MRSA, VRE). Numerous sites were sampled
using reference susceptibility methods.
Methods: Eleven sites forwarded 1,714 strains to a
regional monitor (WCH, Adelaide, Australia) that sus-
ceptibility tested 27 antimicrobials by CLSI methods
(M7-A7, 2006). Identiﬁcations were conﬁrmed and inter-
pretive/screening criteria were also by CLSI guidelines
(M100-S18, 2008), except for tigecycline where United
States - Food and Drug Administration breakpoints were
applied. Major pathogens were: S. aureus (250), coagulase-
negative staphylococci (CoNS; 228), enterococci (93),
Enterobacters (76), E. coli (217), K. pneumoniae (268),
Salmonella spp. (55) and Acinetobacters (108).
Results: Tigecycline was active against 98—100% of indi-
cated/tabulated species, lowest for Acinetobacter spp.
S. aureus tigecycline MIC90 values were not inﬂuenced
by oxacillin susceptibility patterns (0.25mg/L; 100% S).
Increased resistance patterns noted were: tetracycline-
resistant (4—100%; average 53%), AmpC, ESBL- and
ﬂuoroquinolone resistance in Enterobacteriaceae (8—70,
14—78, 1—91%, respectively), VRE (1%), MRSA (36%) and
Acinetobacters carbapenem-resistant (38%). S. typhi and S.
paratyphi were common (tigecycline MIC90, 0.5mg/L), and
84% were nalidixic acid-resistant. Carbapenem resistance in
Enterobacteriaceae (1—7%) was consistent with harbouring
metallo--lactamases; conﬁrmed by PCR testing.
Conclusions: Although MDR rates across Gram-positive
and -negative species (particularly among enteric bacilli
and Acinetobacters) was high in India, tigecycline remained
active (MIC90, 1mg/L overall) against these MDR strains.
Tigecycline exhibited promising spectrum/potency exceed-
ing currently available agents against sampled isolates from
India.
doi:10.1016/j.ijid.2008.05.1060
